This test is most useful if any of these apply to you.
Kidney stones that start young or keep coming back can have an inherited cause. Urine cystine testing helps identify cystinuria, a condition in which your kidneys lose too much cystine into urine. It's an established diagnostic measurement, though a spot result alone doesn't identify your genetic variants or predict how often you'll form stones.
Cystinuria affects about 1 in 7,000 people worldwide, with substantial differences between populations. It accounts for a larger share of childhood stones than adult stones. In a multicenter study of 28 adults with cystinuria, diagnosis came an average of 6.4 years after the first stone.
Cystine consists of two cysteine molecules joined through their sulfur atoms. Cysteine is an amino acid used to build proteins. Your kidneys filter cystine from your blood and normally reclaim most of it through a transport protein in the kidney's small tubes.
The genes SLC3A1 and SLC7A9 provide instructions for the two parts of this transport protein. Changes that impair its function allow more cystine to escape into urine. The same transporter reclaims ornithine, lysine and arginine, so these amino acids are often increased too. Cystine forms stones because it dissolves much less readily than the other three.
This quantitative test measures cystine in a spot urine sample using liquid chromatography with mass spectrometry. The method separates compounds before identifying them by mass. The result is expressed relative to urine creatinine, which reduces the effect of how dilute or concentrated the sample is. Creatinine is a waste product produced by muscles.
A spot cystine-to-creatinine ratio, total daily cystine excretion and cystine concentration describe different things. Most treatment and outcome studies used 24-hour collections. Their findings help explain cystine stone disease, but daily excretion and concentration figures can't be applied directly to your spot ratio.
Cystinuria most often involves disease-causing changes in both copies of SLC3A1 or SLC7A9, usually inherited from different parents. Some people with a change in only one copy can also have increased urinary cystine or develop stones, particularly with SLC7A9. The amount in urine doesn't reliably establish which genetic pattern you have.
Stones often begin in childhood or young adulthood, but a first stone later in life doesn't exclude cystinuria. Severity varies widely, including between relatives with the same variants. Genetic testing can clarify inheritance, but it doesn't reliably predict your future stone burden.
Most people with one altered copy of SLC3A1 have normal urine cystine; certain variants are exceptions. A single altered SLC7A9 copy more often raises urinary cystine, and some carriers develop stones. A modest increase therefore needs interpretation alongside the other urinary amino acids, your age and your stone history.
Single-gene stone disorders are uncommon in unselected adult stone formers. In a genetic study of 787 adults with kidney stones, 2.9% had such a disorder, and cystinuria was among the most common diagnoses. This finding came from genetic testing and clinical assessment, not from a spot cystine result alone.
In one study of an extended family, several relatives had substantially increased urinary cystine without any history of stones, many of them well into adulthood. Their measurements came from timed collections. Increased excretion can exist for years without causing a stone.
Stone formation depends on how much cystine is present compared with how much your urine can keep dissolved. Urine volume affects its concentration, and acidity affects its solubility. More alkaline urine holds more cystine in solution.
In a study using 24-hour collections, people whose first cystine stone occurred later in life had similar daily cystine excretion to those who developed stones earlier, but generally produced more urine. Their urine was less overloaded with cystine relative to its ability to dissolve it. This was an association, not proof that urine volume alone determined when stones began.
Cystine capacity measures whether your urine can dissolve additional cystine or instead promotes crystal growth. It has been associated with stone activity, but its predictive accuracy is limited. Neither capacity nor a spot cystine ratio can guarantee that you'll remain stone-free.
Cystinuria is associated with chronic kidney disease, and a minority of affected people develop kidney failure. Repeated obstruction, infections and loss of kidney tissue can contribute. Studies linking kidney impairment to previous procedures don't establish that every procedure caused damage, since people with more severe stones also need more treatment.
Researchers have also found increased inflammation-related proteins in urine from people with cystinuria. These are different measurements from urinary cystine. Their ability to predict future kidney decline remains unproven.
Cystinosis results from changes in CTNS that cause cystine to accumulate inside cells. Its most common form begins in infancy and causes the kidneys to lose salts, glucose and amino acids. Diagnosis uses white blood cell cystine measurements and genetic testing. Urinary cystine can also increase with this broader loss of amino acids, so an increased urine result isn't specific to cystinuria.
The inherited transport problem persists, but urinary cystine can change with diet and treatment. Repeat measurements can help assess those changes when the specimen format and method remain consistent. Treatment can also reduce stone risk through changes in urine volume or acidity without lowering the spot ratio, so follow-up includes those measurements and evidence of stone growth or recurrence.
Evidence-backed interventions that affect your Cystine level
Cystine is best interpreted alongside these tests.
Cystine is included in these pre-built panels.
A comprehensive at-home nutritional and metabolic assessment that analyzes key biomarkers to reveal functional nutrient needs and imbalances.